| Array BioPharma is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer and other diseases. Co.'s commercial and clinical stage drugs include: BRAFTOVI + MEKTOVI, which are BRAF and MEK inhibitors for BRAF-mutant melanoma; Encorafenib, a BRAF inhibitor for BRAF-mutant colorectal cancer (CRC); Binimetinib, a MEK inhibitor for CRC and other cancers; Selumetinib, a MEK inhibitor for cancer and Neurofibromatosis type 1; Ganovo/Danoprevir, a protease inhibitor for Hepatitis C virus; Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy. We show 38 historical shares outstanding datapoints in our ARRY shares outstanding history coverage, used to compute ARRY market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARRY market cap history over the course of time is important for investors
interested in comparing ARRY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARRY versus a peer is one thing; comparing
ARRY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARRY can fluctuate over the course of history.
With this page we aim to empower investors researching ARRY by allowing them to research the ARRY market cap history.